Cantor Fitzgerald Upgrades Omeros to Overweight After Stronger Yartemlea Launch
Doctors see 35%–40% U.S. share; peak sales estimate raised to about $400 million.
/ 185 items
#XY Analyst Up/Down↓
BofA Upgrades Candel Therapeutics to Buy as Prostate Cancer Filing Nears
Prostate data look filing-ready, cash is $201.6M, and analysts see ~66% upside.
Barclays Calls Helus Pharma’s Friday Selloff a Buying Opportunity After $35 Initiation
Helus Pharma sold off Friday after Barclays’ $35 initiation. The bank says APPROACH data are not the sole basis for its rating.
Roth Capital Starts MediciNova at Buy With $6 Target on ALS Drug
Phase 2b/3 ALS data due Q4 2026; cash runway into late 2027.
Barclays Upgrades Alvotech to Overweight, Doubles Target to $8 Ahead of December FDA Decisions
Barclays now sees two-times upside vs. downside for ALVO into December FDA reviews of Simponi, Eylea and Prolia biosimilars.
Needham Upgrades Rocket Pharmaceuticals After FDA Clears Path for Danon Gene Therapy Trial
FDA let Rocket keep its 12-patient Danon study and count the first 3 patients. Needham upgraded RCKT and removed a key regulatory overhang.